Navigation Links
Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
Date:6/7/2011

FORT WORTH, Texas, June 7, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at two upcoming investment conferences.  The first presentation is scheduled for 2:30 pm(EDT) on Thursday, June 9, 2011 during the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt Hotel in New York, NY. The second is scheduled for 10:15 am (EDT) on Thursday, June 23, 2011 during the 2011 Wells Fargo Securities Healthcare Conference at The InterContinental Boston in Boston, MA.

The presentations will include updates on the Company's ongoing commercial operations, its recent acquisition of Regranex® Gel and phase 2b summary results for its cell therapy pipeline candidate for chronic wounds (HP802-247).

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. The company's research and development strategy is presently centered around next-generation cell-based therapies for the treatment of chronic wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® Gel. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com®. Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpointbio.com.

HEALTHPOINT, SANTYL, THE WOUND INSTITUTE, THEWOUNDINSTITUTE.COM and REGRANEX are registered trademarks of Healthpoint, Ltd.

OASIS is a registered trademark of Cook Biotech, Inc.


'/>"/>
SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
2. Healthpoint Launches New Corporate Identity
3. Healthpoint to Present at 29th Annual J.P. Morgan Healthcare Conference
4. Healthpoint Launches Collagenase SANTYL(R) Ointment in Canada
5. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
6. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
7. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
8. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
9. Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial
10. Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff
11. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
Breaking Medicine Technology:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... The threat ... went to work for a company involved in the underground testing of nuclear weapons. ... “Dying for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the ...
(Date:2/27/2017)... ... , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and ... for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss ... compiled into a single volume a compelling argument that the disease does exist in ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five ... genders. And the need for advanced services is growing. , Project WE vs ... program, in collaboration with their non-profit partners in their fight against cancer and in ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC ... North America, today announced it would be offering some it’s exclusive product line ... on crafting quality and unique baby clothing/feeding products, will team up with AMAZON ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... (PD) in persons with a specific LRRK2 mutation, according to a study released ... studies have provided evidence of a link between pesticides and incidence of sporadic ...
Breaking Medicine News(10 mins):